Keith Krehbiel, a Parkinson’s disease patient, lived with the condition for nearly 25 years before considering a brain implant to alleviate his symptoms. Despite his initial reluctance, he eventually agreed to undergo the surgery in 2020 as his symptoms worsened. The procedure, known as deep-brain stimulation, involves inserting thin wires into the brain to deliver electrical pulses and normalize brain activity associated with movement disorders.
Since the approval of deep-brain stimulation devices almost three decades ago, over 200,000 individuals have benefitted from the treatment. However, recent advancements in technology have introduced adaptive deep-brain stimulation (aDBS), which can read brain waves and tailor the rhythm of electrical output to improve symptom management. Helen Bronte-Stewart, a neurologist at Stanford University, spearheaded a clinical trial called ADAPT-PD to test the efficacy of aDBS in 68 participants, including Keith Krehbiel.
The results of the ADAPT-PD trial, which are currently under review for publication, have shown promising outcomes and have received approval from regulators in the US and Europe. This breakthrough could significantly impact the lives of millions of individuals living with Parkinson’s disease and open doors for Medtronic, the company manufacturing the implants, as well as other companies developing advanced devices for neurological conditions.
The success of aDBS in Parkinson’s disease has paved the way for its application in other movement disorders such as Tourette’s syndrome, essential tremor, and obsessive-compulsive disorder. Researchers are exploring the potential of aDBS to address a wide range of neurological and psychiatric conditions, including treatment-resistant depression. The technology’s ability to automatically adjust stimulation based on brain activity could revolutionize the field of neuromodulation and offer personalized treatment options for patients.
Despite the promising results of aDBS, challenges remain in terms of funding for further research and development. With the global prevalence of Parkinson’s disease expected to rise significantly in the coming years, there is a growing need for accessible and effective treatments. The integration of artificial intelligence and automation in device programming may streamline the treatment process and improve patient outcomes.
As advancements in deep-brain stimulation continue to evolve, the focus remains on making innovative therapies accessible to individuals like Keith Krehbiel, who have experienced significant improvements in their quality of life. By leveraging cutting-edge technology and research, the future of neuromodulation holds immense potential for transforming the lives of those affected by neurological disorders.
This rewritten content is based on the original article published on July 15, 2025, and highlights the key points and advancements in deep-brain stimulation technology for Parkinson’s disease and other neurological conditions.
